Written Question·Department of Health and Social Care·UIN HL16087

Blood Cancer: Medical Treatments

Tabled: 26 March 2026

Question

To ask His Majesty's Government what assessment they have made of the consequences for patients with mantle cell lymphoma of NICE’s decisions not to recommend (1) brexucabtagene autoleucel, and (2) acalabrutinib with bendamustine and rituximab; and what s